Mesa Laboratories, Inc. (NASDAQ: MLAB) Stock Competitors & Peer Comparison

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, ALC has a market cap of 34.4B. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while ALC trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas ALC's P/E ratio is 22.17. In terms of profitability, MLAB's ROE is +0.03%, compared to ALC's ROE of +0.03%. Regarding short-term risk, MLAB is more volatile compared to ALC. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check ALC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, STE has a market cap of 21.9B. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while STE trades at $224.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas STE's P/E ratio is 21.56. In terms of profitability, MLAB's ROE is +0.03%, compared to STE's ROE of +0.11%. Regarding short-term risk, MLAB is more volatile compared to STE. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check STE's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, QDEL has a market cap of 952.6M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while QDEL trades at $13.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas QDEL's P/E ratio is 10.43. In terms of profitability, MLAB's ROE is +0.03%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, MLAB is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check QDEL's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, BWAY has a market cap of 555M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while BWAY trades at $14.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas BWAY's P/E ratio is 35.95. In terms of profitability, MLAB's ROE is +0.03%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, MLAB is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check BWAY's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, SI has a market cap of 421.4M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while SI trades at $20.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas SI's P/E ratio is -10.61. In terms of profitability, MLAB's ROE is +0.03%, compared to SI's ROE of -0.26%. Regarding short-term risk, MLAB is less volatile compared to SI. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check SI's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, MASS has a market cap of 412.3M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while MASS trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas MASS's P/E ratio is -16.75. In terms of profitability, MLAB's ROE is +0.03%, compared to MASS's ROE of -0.25%. Regarding short-term risk, MLAB is less volatile compared to MASS. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check MASS's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, MOBI has a market cap of 386.7M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while MOBI trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas MOBI's P/E ratio is -0.62. In terms of profitability, MLAB's ROE is +0.03%, compared to MOBI's ROE of -15.96%. Regarding short-term risk, MLAB is less volatile compared to MOBI. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check MOBI's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, ANIK has a market cap of 278.5M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while ANIK trades at $20.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas ANIK's P/E ratio is 42.47. In terms of profitability, MLAB's ROE is +0.03%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, MLAB is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check ANIK's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, LAB has a market cap of 268.3M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while LAB trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas LAB's P/E ratio is -9.79. In terms of profitability, MLAB's ROE is +0.03%, compared to LAB's ROE of -0.18%. Regarding short-term risk, MLAB is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check LAB's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, TRIB has a market cap of 190.6M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while TRIB trades at $9.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas TRIB's P/E ratio is -0.16. In terms of profitability, MLAB's ROE is +0.03%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, MLAB is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check TRIB's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while EDAP trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas EDAP's P/E ratio is -5.80. In terms of profitability, MLAB's ROE is +0.03%, compared to EDAP's ROE of -3.13%. Regarding short-term risk, MLAB is less volatile compared to EDAP. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check EDAP's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, NYXH has a market cap of 162.1M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while NYXH trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas NYXH's P/E ratio is -0.64. In terms of profitability, MLAB's ROE is +0.03%, compared to NYXH's ROE of -1.80%. Regarding short-term risk, MLAB is less volatile compared to NYXH. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check NYXH's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, APYX has a market cap of 128.4M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while APYX trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas APYX's P/E ratio is -15.25. In terms of profitability, MLAB's ROE is +0.03%, compared to APYX's ROE of -0.79%. Regarding short-term risk, MLAB is more volatile compared to APYX. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check APYX's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, SKIN has a market cap of 88.8M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while SKIN trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas SKIN's P/E ratio is -3.11. In terms of profitability, MLAB's ROE is +0.03%, compared to SKIN's ROE of -0.48%. Regarding short-term risk, MLAB is less volatile compared to SKIN. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check SKIN's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, DRIO has a market cap of 52.9M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while DRIO trades at $7.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas DRIO's P/E ratio is -1.24. In terms of profitability, MLAB's ROE is +0.03%, compared to DRIO's ROE of +1.04%. Regarding short-term risk, MLAB is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check DRIO's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, MDAI has a market cap of 50M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while MDAI trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas MDAI's P/E ratio is -3.49. In terms of profitability, MLAB's ROE is +0.03%, compared to MDAI's ROE of +1.21%. Regarding short-term risk, MLAB is more volatile compared to MDAI. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check MDAI's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, BEAT has a market cap of 23.7M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while BEAT trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas BEAT's P/E ratio is -0.84. In terms of profitability, MLAB's ROE is +0.03%, compared to BEAT's ROE of -6.87%. Regarding short-term risk, MLAB is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check BEAT's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, BEATW has a market cap of 8.4M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while BEATW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas BEATW's P/E ratio is -0.02. In terms of profitability, MLAB's ROE is +0.03%, compared to BEATW's ROE of -6.87%. Regarding short-term risk, MLAB is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check BEATW's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, WOK has a market cap of 5.1M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while WOK trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas WOK's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.03%, compared to WOK's ROE of -0.19%. Regarding short-term risk, MLAB is less volatile compared to WOK. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check WOK's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while QTEXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas QTEXW's P/E ratio is -0.01. In terms of profitability, MLAB's ROE is +0.03%, compared to QTEXW's ROE of N/A. Regarding short-term risk, MLAB is less volatile compared to QTEXW. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check QTEXW's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, FEED has a market cap of 3.1M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while FEED trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas FEED's P/E ratio is -0.03. In terms of profitability, MLAB's ROE is +0.03%, compared to FEED's ROE of -0.60%. Regarding short-term risk, MLAB is less volatile compared to FEED. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check FEED's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, ITOC has a market cap of 2.8M. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while ITOC trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas ITOC's P/E ratio is -0.95. In terms of profitability, MLAB's ROE is +0.03%, compared to ITOC's ROE of -0.94%. Regarding short-term risk, MLAB is less volatile compared to ITOC. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check ITOC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 715M. In comparison, TIVC has a market cap of 279.2K. Regarding current trading prices, MLAB is priced at $127.78 on the NASDAQ, while TIVC trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 12.89, whereas TIVC's P/E ratio is -0.04. In terms of profitability, MLAB's ROE is +0.03%, compared to TIVC's ROE of -1.65%. Regarding short-term risk, MLAB is less volatile compared to TIVC. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check TIVC's competition here